Media Coverage
Read how VistaGen’s intention to revolutionize mental health medicine is causing a buzz in the media.

An interview with Shawn Singh: Chief Executive Officer and Director of VistaGen Therapeutics

VistaGen’s Antidepressant Nasal Spray Succeeds Phase 2a Trial

FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia

Investigational Dyskinesia Treatment Gets FDA Green Light

VistaGen to study dyskinesia drug in Phase II Parkinson’s trial

FDA Clears Study to Test New Drug to Treat Dyskinesia for Parkinson Patients

Intranasal Therapy Fast-Tracked for Social Anxiety Disorder

Long-Term Use of Benzodiazepines – Avoiding Another Drug Crisis

Advancing AV-101